Louisiana jury awards $10 million against J&J in talc mesothelioma case

1 min read | Published on 24 Aug 2026, 09:58 PM |Updated on 24 Aug 2026, 09:58 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Louisiana jury awards $10 million in damages against Johnson & Johnson
Verdict includes $8 million for pain/suffering and $1 million each to two daughters
J&J's specific liability share set at over $1.2 million due to multiple defendants
Jury found company negligent for failing to warn about asbestos hazards

*this image is generated using AI for illustrative purposes only.

A Louisiana jury has awarded $10 million in damages to the family of Lynne Roy, ruling that Johnson & Johnson’s negligence regarding asbestos exposure contributed to her death from mesothelioma.

The verdict follows a three-week trial in the Civil District Court for Orleans Parish in New Orleans. The jury concluded that Ms. Roy suffered significant exposure to asbestos from products manufactured or sold by Johnson & Johnson, which was a significant cause of her developing the lung disease.

Verdict Breakdown

The total award reflects distinct components for physical damages and loss of companionship. The jury determined Johnson & Johnson was negligent and its products were unreasonably dangerous, citing a failure to warn about asbestos hazards.

Category	Amount	Recipient
Physical pain and suffering	$8 million	Estate of Lynne Roy
Loss of mother	$1 million	Melissa Kaiser
Loss of mother	$1 million	Melanie Roy
Total Award	$10 million

What the Numbers Show

While the total verdict stands at $10 million, Johnson & Johnson’s specific financial liability is significantly lower due to shared responsibility. The jury determined that other defendants, including additional talc companies and firms that intentionally included asbestos in their products, were also significant factors in Ms. Roy’s death. Consequently, Johnson & Johnson’s share of the verdict was set at over $1.2 million.

Legal Context

Dean Omar Branham Shirley, LLP (DOBS) represented the plaintiffs. Attorneys Danny Kraft and Darren McDowell led the trial team. Jessica Dean, a partner at DOBS, noted that the daughters waited over six years for the trial, largely due to two bad faith bankruptcies initiated by Johnson & Johnson.

This marks the 11th talc trial victory against Johnson & Johnson for DOBS across half a dozen states. The firm has additional talc trials scheduled against the company later this year. The case, Lynne L. Roy v. Colgate-Palmolive Company, et al., No. 2020-02718, was filed in the Civil District Court for Orleans Parish.

How might this verdict influence Johnson & Johnson's strategy regarding its ongoing bankruptcy proceedings and settlement negotiations?

What is the potential impact on J&J's stock price and investor confidence given the accumulation of talc-related liabilities?

Could this ruling set a precedent that accelerates similar mesothelioma claims in other jurisdictions where J&J faces litigation?

Johnson & Johnson secures FDA clearance for MONARCH QUEST 3

1 min read | Published on 19 Aug 2026, 10:51 PM |Updated on 19 Aug 2026, 10:51 PM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Johnson & Johnson (NYSE: JNJ) has obtained FDA 510(k) clearance for MONARCH QUEST 3, advancing its robotic bronchoscopy platform with AI-driven nodule segmentation and improved 3D navigation. The update integrates with the Polyphonic digital ecosystem to streamline procedural data review. This is the fourth major update to the MONARCH system in 18 months, highlighting J&J's focus on continuous software innovation in medical robotics.

*this image is generated using AI for illustrative purposes only.

Johnson & Johnson (NYSE: JNJ) secured US 510(k) regulatory clearance on Monday for MONARCH QUEST 3, the latest software iteration for its robotically-assisted bronchoscopy platform. The update introduces AI-powered nodule segmentation and a 3D Compass overlay to improve navigation accuracy during complex airway procedures. This marks the fourth launch for the MONARCH system in the past 18 months.

The MONARCH system operates as the first flexible, robotically-assisted platform designed to help physicians visualize and access patient airways for diagnostic and therapeutic procedures. With the QUEST 3 update, the healthcare company addresses anatomical changes and CT-to-body divergence that frequently happen during clinical interventions, giving physicians precise control and stable reach.

AI And Imaging Upgrades

The software release introduces AI-powered nodule segmentation, allowing clinicians to automatically generate accurate nodule boundaries with a single click before a procedure begins. It also deploys software enhancements to improve navigation accuracy as a patient’s anatomy shifts.

Additionally, a new 3D Compass overlay simplifies scope-tip orientation by aligning joystick movements with patient anatomy. The software expands compatibility with mobile and fixed cone-beam computed tomography (CBCT) imaging systems, enabling medical facilities to use current imaging infrastructure to better target lung nodules.

Integrating Digital Ecosystems

MONARCH QUEST 3 incorporates Polyphonic, the open digital ecosystem developed by Johnson & Johnson. The integration extends surgical intelligence beyond the operating room. Clinicians can review procedural volume data and collaborate with colleagues through a centralized video library. Polyphonic organizes each case into a consistent format, making it easier for medical teams to revisit key moments and support ongoing learning.

What the Numbers Show

The rapid deployment of four distinct software launches for the MONARCH system within an 18-month window indicates a high-frequency innovation cycle focused on software-defined value rather than solely hardware iterations. This pattern suggests a strategic shift toward leveraging digital ecosystems like Polyphonic to enhance clinical utility and user retention through continuous feature updates.

Price Action

Johnson & Johnson shares were up 0.58% at $272.68 at the time of publication on Wednesday, according to Benzinga Pro data.

How might the integration of AI-powered nodule segmentation impact the adoption rate of the MONARCH system among smaller medical facilities with limited imaging infrastructure?

What are the potential regulatory hurdles for expanding MONARCH QUEST 3's capabilities to therapeutic interventions beyond current diagnostic uses?

How will Johnson & Johnson's shift toward a software-defined innovation cycle affect its long-term revenue streams compared to traditional hardware sales models?